These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 26238323)

  • 1. Discovery and structure-guided optimization of tert-butyl 6-(phenoxymethyl)-3-(trifluoromethyl)benzoates as liver X receptor agonists.
    Matsui Y; Yamaguchi T; Yamazaki T; Yoshida M; Arai M; Terasaka N; Honzumi S; Wakabayashi K; Hayashi S; Nakai D; Hanzawa H; Tamaki K
    Bioorg Med Chem Lett; 2015 Sep; 25(18):3914-20. PubMed ID: 26238323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and pharmacology of 1,1-bistrifluoromethylcarbinol derivatives as liver X receptor β-selective agonists.
    Koura M; Matsuda T; Okuda A; Watanabe Y; Yamaguchi Y; Kurobuchi S; Matsumoto Y; Shibuya K
    Bioorg Med Chem Lett; 2015 Jul; 25(13):2668-74. PubMed ID: 25998501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 4-(3-Aryloxyaryl)quinoline sulfones are potent liver X receptor agonists.
    Bernotas RC; Singhaus RR; Kaufman DH; Travins JM; Ullrich JW; Unwalla R; Quinet E; Evans M; Nambi P; Olland A; Kauppi B; Wilhelmsson A; Goos-Nilsson A; Wrobel J
    Bioorg Med Chem Lett; 2010 Jan; 20(1):209-12. PubMed ID: 19932617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver X receptor (LXR) partial agonists: biaryl pyrazoles and imidazoles displaying a preference for LXRβ.
    Kick E; Martin R; Xie Y; Flatt B; Schweiger E; Wang TL; Busch B; Nyman M; Gu XH; Yan G; Wagner B; Nanao M; Nguyen L; Stout T; Plonowski A; Schulman I; Ostrowski J; Kirchgessner T; Wexler R; Mohan R
    Bioorg Med Chem Lett; 2015 Jan; 25(2):372-7. PubMed ID: 25435151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and optimization of a series of liver X receptor antagonists.
    Jiao X; Kopecky DJ; Fisher B; Piper DE; Labelle M; McKendry S; Harrison M; Jones S; Jaen J; Shiau AK; Escaron P; Danao J; Chai A; Coward P; Kayser F
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5966-70. PubMed ID: 22901900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The medicinal chemistry of liver X receptor (LXR) modulators.
    Tice CM; Noto PB; Fan KY; Zhuang L; Lala DS; Singh SB
    J Med Chem; 2014 Sep; 57(17):7182-205. PubMed ID: 24832115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent progress in liver X receptor-selective modulators.
    Ratni H; Wright MB
    Curr Opin Drug Discov Devel; 2010 Jul; 13(4):403-13. PubMed ID: 20597026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4-(3-aryloxyaryl)quinoline alcohols are liver X receptor agonists.
    Bernotas RC; Kaufman DH; Singhaus RR; Ullrich J; Unwalla R; Quinet E; Nambi P; Wilhelmsson A; Goos-Nilsson A; Wrobel J
    Bioorg Med Chem; 2009 Dec; 17(23):8086-92. PubMed ID: 19853462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Delivery of LXR Agonist Using a Site-Specific Antibody-Drug Conjugate.
    Lim RK; Yu S; Cheng B; Li S; Kim NJ; Cao Y; Chi V; Kim JY; Chatterjee AK; Schultz PG; Tremblay MS; Kazane SA
    Bioconjug Chem; 2015 Nov; 26(11):2216-22. PubMed ID: 25945727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of 4-(3-biaryl)quinoline sulfones as potent liver X receptor agonists.
    Ullrich JW; Morris R; Bernotas RC; Travins JM; Jetter J; Unwalla R; Quinet E; Nambi P; Feingold I; Huselton C; Enroth C; Wilhelmsson A; Goos-Nilsson A; Wrobel J
    Bioorg Med Chem Lett; 2010 May; 20(9):2903-7. PubMed ID: 20382019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Light-Activated LXR Agonists.
    Mukhopadhyay TK; Willems S; Arp CJ; Morstein J; Haake CT; Merk D; Trauner D
    ChemMedChem; 2023 Jun; 18(11):e202200647. PubMed ID: 36896647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver X receptor modulators: a review of recently patented compounds (2007 - 2009).
    Li X; Yeh V; Molteni V
    Expert Opin Ther Pat; 2010 Apr; 20(4):535-62. PubMed ID: 20302451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a Novel, Orally Efficacious Liver X Receptor (LXR) β Agonist.
    Zheng Y; Zhuang L; Fan KY; Tice CM; Zhao W; Dong C; Lotesta SD; Leftheris K; Lindblom PR; Liu Z; Shimada J; Noto PB; Meng S; Hardy A; Howard L; Krosky P; Guo J; Lipinski K; Kandpal G; Bukhtiyarov Y; Zhao Y; Lala D; Van Orden R; Zhou J; Chen G; Wu Z; McKeever BM; McGeehan GM; Gregg RE; Claremon DA; Singh SB
    J Med Chem; 2016 Apr; 59(7):3264-71. PubMed ID: 26990539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis.
    Wrobel J; Steffan R; Bowen SM; Magolda R; Matelan E; Unwalla R; Basso M; Clerin V; Gardell SJ; Nambi P; Quinet E; Reminick JI; Vlasuk GP; Wang S; Feingold I; Huselton C; Bonn T; Farnegardh M; Hansson T; Nilsson AG; Wilhelmsson A; Zamaratski E; Evans MJ
    J Med Chem; 2008 Nov; 51(22):7161-8. PubMed ID: 18973288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The discovery of tertiary-amine LXR agonists with potent cholesterol efflux activity in macrophages.
    Marino JP; Kallander LS; Ma C; Oh HJ; Lee D; Gaitanopoulos DE; Krawiec JA; Parks DJ; Webb CL; Ziegler K; Jaye M; Thompson SK
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5617-21. PubMed ID: 19717304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and biological evaluation of novel transrepression-selective liver X receptor (LXR) ligands with 5,11-dihydro-5-methyl-11-methylene-6H-dibenz[b,e]azepin-6-one skeleton.
    Aoyama A; Endo-Umeda K; Kishida K; Ohgane K; Noguchi-Yachide T; Aoyama H; Ishikawa M; Miyachi H; Makishima M; Hashimoto Y
    J Med Chem; 2012 Sep; 55(17):7360-77. PubMed ID: 22873709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3-(3-Aryloxyaryl)imidazo[1,2-a]pyridine sulfones as liver X receptor agonists.
    Singhaus RR; Bernotas RC; Steffan R; Matelan E; Quinet E; Nambi P; Feingold I; Huselton C; Wilhelmsson A; Goos-Nilsson A; Wrobel J
    Bioorg Med Chem Lett; 2010 Jan; 20(2):521-5. PubMed ID: 20005711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver X receptor agonist GW3965 dose-dependently regulates lps-mediated liver injury and modulates posttranscriptional TNF-alpha production and p38 mitogen-activated protein kinase activation in liver macrophages.
    Wang YY; Dahle MK; Steffensen KR; Reinholt FP; Collins JL; Thiemermann C; Aasen AO; Gustafsson JA; Wang JE
    Shock; 2009 Nov; 32(5):548-53. PubMed ID: 19295476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of liver X receptor attenuates endothelin-1 expression in vascular endothelial cells.
    Gao M; Zeng Y; Guan Y; Hu Z; Zhong D; Shen X; Zhang L; Xu Z; Gong W; Zhang Y; Zhang M; Zheng Y; He F
    Int J Biochem Cell Biol; 2012 Dec; 44(12):2299-307. PubMed ID: 23018104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and Synthesis of a Novel Series of Liver X Receptor Antagonists.
    Nian S; Gan X; Tan X; Yu Z; Wang P; Chen X; Wang G
    Chem Pharm Bull (Tokyo); 2015; 63(8):628-35. PubMed ID: 26062802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.